Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: SmithKline Beecham

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham: "Don't expect us to make another big acquisition tomorrow," SB Chairman and CEO Jan Leschly told Alex. Brown May 17, as the company must make the necessary synergies with its 1994 buying spree. Last year, SmithKline acquired pharmacy benefit management firm DPS in May for $2.3 bil., bought Sterling Health for $2.9 bil. in August and divested Sterling Health North America in September for $1 bil. ("The Tan Sheet" Sept. 19, 1994, pp. 1-4). In November, SB sold its animal health business to Pfizer for $1.45 bil. SmithKline will continue investing in numerous small company collaborative ventures, Leschly noted. SmithKline has made 130 deals in the last three years with small or start-up companies, he noted...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel